

**Supplemental Table 1** Demographics and baseline clinical characteristics in the DYNAGITO study (treated set)

	Japanese subgroup			Overall study population		
	TIO 5 µg (n=235)	TIO+OLO 5/5 µg (n=226)	Total (n=461)	TIO 5 µg (n=3941)	TIO+OLO 5/5 µg (n=3939)	Total (n=7880)
Male, n (%)	224 (95.3)	210 (92.9)	434 (94.1)	2841 (72.1)	2785 (70.7)	5626 (71.4)
Age, years	71.4 (7.5)	71.8 (6.9)	71.6 (7.2)	66.3 (8.5)	66.5 (8.4)	66.4 (8.5)
Body mass index, kg/m <sup>2</sup>	21.4 (3.6)	21.4 (3.4)	21.4 (3.5)	26.2 (5.8)	26.3 (5.9)	26.3 (5.8)
Smoking status, n (%)						
Never smoked	0 (0.00)	0 (0.00)	0 (0.00)	1 (0.0)	0 (0.0)	1 (0.0)
Ex-smoker	196 (83.4)	188 (83.2)	384 (83.3)	2462 (62.5)	2505 (63.6)	4967 (63.0)
Current smoker	39 (16.6)	38 (16.8)	77 (16.7)	1478 (37.5)	1434 (36.4)	2912 (37.0)
Smoking history, pack-years	63.7 (32.0)	61.1 (31.1)	62.5 (31.6)	44.7 (25.2)	44.8 (24.4)	44.8 (24.8)
Duration of diagnosis, years	5.8 (5.6)	6.3 (5.4)	6.1 (5.5)	8.0 (6.6)	7.9 (6.6)	8.0 (6.6)
Post-bronchodilator at screening						
FEV <sub>1</sub> , L	1.097 (0.314)	1.040 (0.330)	1.069 (0.323)	1.197 (0.377)	1.177 (0.385)	1.187 (0.381)
FVC, L	2.861 (0.689)	2.804 (0.731)	2.833 (0.710)	2.622 (0.799)	2.586 (0.794)	2.604 (0.797)

FEV <sub>1</sub> /FVC, %	38.8 (8.7)	37.5 (9.2)	38.2 (9.0)	46.7 (11.0)	46.5 (11.0)	46.6 (11.0)
% of predicted normal FEV <sub>1</sub>	44.3 (12.6)	41.7 (11.0)	43.0 (11.9)	44.5 (11.5)	44.6 (37.5)	44.5 (27.7)
GOLD grade base on post-bronchodilator FEV <sub>1</sub> % predicted, n (%)						
I ( $\geq 80\%$ )	3 (1.3)	0 (0.0)	3 (0.7)	20 (0.5)	27 (0.7)	47 (0.6)
II ( $\geq 50\% \text{ to } < 80$ )	80 (34.0)	61 (27.0)	141 (30.6)	1436 (36.4)	1348 (34.2)	2784 (35.3)
III ( $\geq 30\% \text{ to } < 50$ )	121 (51.5)	125 (55.3)	246 (53.4)	2011 (51.0)	2028 (51.5)	4039 (51.3)
IV ( $< 30\%$ )	31 (13.2)	39 (17.3)	70 (15.2)	467 (11.8)	525 (13.3)	992 (12.6)
Missing	0 (0.0)	1 (0.4)	1 (0.2)	7 (0.2)	11 (0.3)	18 (0.2)
Exacerbation history in previous year, n (%)						
Only 1 moderate exacerbation	118 (50.2)	104 (46.0)	222 (48.2)	2207 (56.0)	2184 (55.4)	4391 (55.7)
$\geq 2$ moderate or $\geq 1$ severe exacerbation	117 (49.8)	122 (54.0)	239 (51.8)	1733 (44.0)	1754 (44.5)	3487 (44.3)
No exacerbation	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.0)	1 (0.0)	2 (0.0)
Baseline pulmonary medication, n (%)						
LABA only	10 (4.3)	3 (1.3)	13 (2.8)	135 (3.4)	122 (3.1)	257 (3.3)

LAMA only	47 (20.0)	44 (19.5)	91 (19.7)	350 (8.9)	365 (9.3)	715 (9.1)
ICS only	1 (0.4)	0 (0.0)	1 (0.2)	93 (2.4)	107 (2.7)	200 (2.5)
LABA+ICS	12 (5.1)	12 (5.3)	24 (5.2)	1005 (25.5)	1031 (26.2)	2036 (25.8)
LAMA+ICS	6 (2.6)	3 (1.3)	9 (2.0)	88 (2.2)	78 (2.0)	166 (2.1)
LAMA+LABA	54 (23.0)	58 (25.7)	112 (24.3)	478 (12.1)	461 (11.7)	939 (11.9)
LAMA+LABA+ICS	96 (40.9)	92 (40.7)	188 (40.8)	1577 (40.0)	1555 (39.5)	3132 (39.7)
Neither LABA, LAMA, nor ICS	9 (3.8)	14 (6.2)	23 (5.0)	215 (5.5)	220 (5.6)	435 (5.5)
SGRQ total score	40.2 (17.0)	40.7 (17.3)	40.4 (17.1)	47.4 (17.7)	48.1 (17.7)	47.7 (17.7)

**Notes:** Data shown are mean (standard deviation), unless otherwise specified

**Abbreviations:** FEV<sub>1</sub>, forced expiratory volume in 1 second; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS, inhaled corticosteroid; LAMA, long-acting muscarinic antagonist; LABA, long-acting β<sub>2</sub>-agonist; OLO, olodaterol; TIO, tiotropium.